Malignant Colorectal Neoplasm — Research

Malignant Colorectal Neoplasm — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-13	169,282	`("Malignant Colorectal Neoplasm"[tiab] OR "Colorectal Cancer"[tiab] OR "Malignant Colorectal Tumor"[tiab])`	2026-09-13	pubmed
Last 5 years	2021-01-01 → 2026-12-31	65,243	`("Malignant Colorectal Neoplasm"[tiab] OR "Colorectal Cancer"[tiab] OR "Malignant Colorectal Tumor"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-13	pubmed
Last 12 months	2025-09-13 → 2026-09-13	14,135	`("Malignant Colorectal Neoplasm"[tiab] OR "Colorectal Cancer"[tiab] OR "Malignant Colorectal Tumor"[tiab]) AND (2025/09/13:2026/09/13[dp])`	2026-09-13	pubmed

Data updated 19 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (357)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 176–200 of 357 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.
· PLoS One · 2014 · PMID 24594804 · validated civic_curation pubmed
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.
· J Clin Oncol · 2017 · PMID 28486044 · validated civic_curation pubmed
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
· JAMA · 2010 · PMID 20978259 · validated civic_curation pubmed
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.